PT001 + PT005

PT001 + PT005 refers to the co-administration of two separate inhaled medications for respiratory disease management. Specifically, it is the combination of glycopyrronium (PT001), a long-acting muscarinic antagonist (LAMA), and formoterol fumarate (PT005), a long-acting beta-2 agonist (LABA). Both are delivered via individual metered dose inhalers. This combination has been studied for its safety and efficacy in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The rationale is that combining bronchodilators with complementary mechanisms can provide greater improvement in lung function than either agent alone[2][5]. The drugs were developed by Pearl Therapeutics using their proprietary co-suspension technology before the company was acquired by AstraZeneca[5].

Other names

GP MDI + FF MDIGlycopyrronium metered dose inhaler + Formoterol Fumarate metered dose inhaler